Physician
Silver Health Care PC
Silver Health Care PC was paid $5.70M by Medicaid between Jan 2018 and Dec 2024, across 114 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 44% of everything it billed.
33Billing provider infoSILVER HEALTH CARE PC
SILVER CITY, NM 88061
SILVER CITY, NM 88061
33aNPI1548291586assigned 07/06/2006
33bProvider typePediatrics Physician
28Total paid$5.70M
24GClaims141,388
24DCodes billed114
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in New Mexico
Rank by total paid#8 of 53
Median peer was paid$535K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,791 | $695K | |
| 2019 | 21,983 | $897K | |
| 2020 | 13,100 | $612K | |
| 2021 | 17,615 | $756K | |
| 2022 | 21,628 | $1.02M | |
| 2023 | 29,754 | $974K | |
| 2024incomplete | 16,517 | $745K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 44% | 27,529 | 25,487 | $2.49M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 26% | 23,519 | 22,207 | $1.47M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 5.5% | 3,137 | 3,122 | $311K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 5.1% | 2,049 | 2,024 | $291K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.7% | 944 | 938 | $154K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.7% | 2,986 | 2,921 | $95K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.1% | 2,719 | 2,681 | $65K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.1% | 903 | 894 | $60K |
| 80053 | Comprehensive metabolic panel | 1.0% | 4,875 | 4,679 | $59K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,176 | 2,157 | $50K |
| 99443 | <1% | 367 | 354 | $44K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 982 | 862 | $36K |
102 more codes
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 279 | $35K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,834 | $33K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,952 | $32K |
| 99177 | <1% | 905 | $31K | |
| 80061 | Lipid panel | <1% | 2,247 | $30K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,145 | $29K |
| 11721 | <1% | 1,441 | $28K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,620 | $27K |
| 92587 | <1% | 1,060 | $24K | |
| S9999 | Sales tax | <1% | 3,793 | $23K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,325 | $22K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 677 | $21K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 166 | $19K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 158 | $17K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 587 | $15K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 772 | $14K |
| 99051 | <1% | 1,518 | $14K | |
| 0012A | <1% | 283 | $11K | |
| 0011A | <1% | 340 | $11K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 100 | $11K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 97 | $10K |
| 90670 | <1% | 84 | $10K | |
| 80050 | General health panel | <1% | 157 | $9K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 258 | $9K |
| 90677 | <1% | 67 | $8K | |
| 99072 | <1% | 230 | $7K | |
| 84439 | <1% | 590 | $6K | |
| 99441 | <1% | 85 | $5K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 77 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 95 | $4K |
| 0013A | <1% | 82 | $4K | |
| 0071A | <1% | 79 | $3K | |
| 85027 | <1% | 563 | $3K | |
| 96127 | <1% | 800 | $3K | |
| 90686 | <1% | 419 | $3K | |
| 11730 | <1% | 54 | $3K | |
| 90756 | <1% | 107 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 47 | $2K |
| 81003 | <1% | 1,651 | $2K | |
| 99080 | <1% | 376 | $2K | |
| 99173 | <1% | 65 | $2K | |
| 83721 | <1% | 228 | $2K | |
| 0072A | <1% | 38 | $2K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 137 | $2K |
| 84481 | <1% | 57 | $1K | |
| 99490 | Ccm add 20min | <1% | 157 | $1K |
| 90688 | <1% | 80 | $1K | |
| 90697 | <1% | 19 | $967.11 | |
| 82607 | <1% | 50 | $816.79 | |
| 11732 | <1% | 42 | $785.43 | |
| 0003A | <1% | 15 | $660.76 | |
| 90680 | <1% | 21 | $641.66 | |
| 82746 | <1% | 34 | $553.34 | |
| 90473 | <1% | 17 | $411.64 | |
| 73630 | <1% | 17 | $389.09 | |
| 81025 | <1% | 45 | $388.72 | |
| 83655 | <1% | 28 | $383.14 | |
| 82728 | <1% | 30 | $380.01 | |
| 85610 | <1% | 160 | $316.67 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 26 | $310.61 |
| 90656 | <1% | 12 | $284.42 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 26 | $274.73 |
| 93000 | <1% | 15 | $265.77 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 27 | $217.67 |
| 83540 | <1% | 32 | $208.04 | |
| 83550 | <1% | 17 | $149.72 | |
| 85651 | <1% | 30 | $127.72 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 14 | $112.44 |
| 85018 | <1% | 33 | $91.02 | |
| 82043 | <1% | 12 | $77.25 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 108 | $66.37 |
| 86140 | <1% | 13 | $65.20 | |
| 85007 | <1% | 13 | $50.33 | |
| G0008 | Administration of influenza virus vaccine | <1% | 27 | $21.00 |
| Q2035 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria) | <1% | 14 | $20.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 31 | $9.32 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 13 | $7.46 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 26 | $2.65 |
| 90685 | <1% | 16 | $0.16 | |
| 91300 | <1% | 46 | $0.03 | |
| 3075F | 0% | 1,051 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 132 | $0.00 |
| 3074F | 0% | 6,689 | $0.00 | |
| 3079F | 0% | 2,813 | $0.00 | |
| 91301 | 0% | 506 | $0.00 | |
| 3080F | 0% | 619 | $0.00 | |
| 4010F | 0% | 40 | $0.00 | |
| G8756 | No documentation of blood pressure measurement, reason not given | 0% | 32 | $0.00 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 90 | $0.00 |
| 91307 | 0% | 137 | $0.00 | |
| 4050F | 0% | 13 | $0.00 | |
| 3078F | 0% | 5,188 | $0.00 | |
| 1160F | 0% | 4,924 | $0.00 | |
| 1159F | 0% | 4,914 | $0.00 | |
| 3077F | 0% | 497 | $0.00 | |
| 4004F | 0% | 191 | $0.00 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 298 | $0.00 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 69 | $0.00 |
| 90672 | 0% | 48 | $0.00 | |
| 90633 | 0% | 13 | $0.00 | |
| 90710 | 0% | 14 | $0.00 | |
| 90671 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSKEE, JAMES (CEO)